A new partnership has been formed between Navigo Proteins and the Belgian nuclear research center SCK CEN to advance the development of targeted radiotheranostic treatments utilizing the radioisotope terbium-161. The collaboration aims to combine Navigo’s protein engineering capabilities with SCK CEN’s expertise in radiochemistry to explore preclinical applications for cancer therapy, focusing on delivering radioactive agents directly to tumor cells to minimize harm to healthy tissue. Preclinical studies are set to commence with the goal of identifying a lead candidate within two to three years. Additionally, pharmaceutical group IBSA is celebrating 40 years under CEO Arturo Licenziati, and Coriolis Pharma has appointed Peter Sölkner to its Board of Directors. Furthermore, a £13 million funding initiative has been announced in the UK to support 14 innovative projects that aim to transform medicine manufacturing.
Mon, 07 Apr 2025 12:10:42 GMT | Labmate Online